Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect Splicing
- 3 May 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 142 (19), 8706-8727
- https://doi.org/10.1021/jacs.0c00768
Abstract
Approximately 95% of human genes are alternatively spliced, and aberrant splicing events can cause disease. One pre-mRNA that is alternatively spliced and linked to neurodegenerative diseases is tau (microtubule-associated protein tau), which can cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) and can contribute to Alzheimer's disease. Here, we describe the design of structure-specific lead small molecules that directly target tau pre-mRNA from sequence. This was followed by hit expansion and analogue synthesis to further improve upon these initial lead molecules. The emergent compounds were assessed for functional activity in a battery of assays, including binding assays and an assay that mimics molecular recognition of tau pre-mRNA by a U1 small nuclear ribonucleoprotein (snRNP) splicing factor. Compounds that emerged from these studies had enhanced potency and selectivity for the target RNA relative to the initial hits, while also having significantly improved drug-like properties. The compounds are shown to directly target tau pre-mRNA in cells, via chemical cross-linking and isolation by pull-down target profiling, and to rescue disease-relevant splicing of tau pre-mRNA in a variety of cellular systems, including primary neurons. More broadly, this study shows that lead, structure-specific compounds can be designed from sequence and then further optimized for their physicochemical properties while at the same time enhancing their activity.Funding Information
- National Institute of Neurological Disorders and Stroke (DP1-NS096898, P01-NS099114)
- NIH Office of the Director (S10-OD021550)
- Pfizer
- National Institute of General Medical Sciences (R01-GM097455)
This publication has 78 references indexed in Scilit:
- Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicingNucleic Acids Research, 2012
- Finding a better path to drug selectivityDrug Discovery Today, 2011
- Efficient Suppression of Gene Expression by Targeting 5′‐UTR‐Based RNA Quadruplexes with Bisquinolinium CompoundsChemBioChem, 2011
- Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike PropertiesACS Chemical Neuroscience, 2010
- How Much Binding Affinity Can be Gained by Filling a Cavity?Chemical Biology & Drug Design, 2010
- Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathiesNature Reviews Drug Discovery, 2009
- Structural Basis for Stabilization of the Tau Pre-mRNA Splicing Regulatory Element by Novantrone (Mitoxantrone)Cell Chemical Biology, 2009
- Stabilization of the Tau Exon 10 Stem Loop Alters Pre-mRNA SplicingOnline Journal of Public Health Informatics, 2006
- Update on NCI in vitro drug screen utilitiesEuropean Journal of Cancer, 2004
- NMRPipe: A multidimensional spectral processing system based on UNIX pipesJournal of Biomolecular NMR, 1995